Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New mapping technique may improve heart rhythm procedure

NCT ID NCT03915691

Disease control Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two ways to do a catheter ablation for a type of fast heartbeat called atrial tachycardia that comes from heart scar tissue. One method uses a new mapping system (Ripple Mapping) to guide the ablation, while the other uses the standard approach. The goal is to see which method better prevents the arrhythmia from coming back within a year. About 200 adults who need this procedure are taking part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Catheter ablation (Ripple Mapping guided or conventional mapping guided)
What this could lead to
If successful, this could identify a more effective ablation technique to reduce the return of atrial tachycardia after the procedure.
What could go wrong
This is a mid-stage study with no phase designation, and the outcome depends on long-term follow-up. The procedure itself carries standard risks like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

201 people

The number who actually took part.

Started

Aug 2022

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Referred for catheter ablation of AT by the direct care team, based on clinical indication. 2. Male or female, aged \>18 years old. 3. Able to consent for recruitment to the trial and the catheter ablation procedure. Exclusion Criteria: 1. Contraindication to catheter ablation as deemed by the clinical team. 2. Typical atrial flutter or AF on ECG.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial tachycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial tachycardia

Contacts and locations

Locations

  • Freeman Hospital, The Newcastle Upon Tyne NHS Foundation Trust

    Newcastle, NE7 7DN, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, W12 0HS, United Kingdom

  • Liverpool Heart & Chest Hospital

    London, L14 3PE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.